ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women
Abstract Background ABO blood groups has been associated with risk of several cancers; however, the results for an association with ovarian cancer are inconsistent and little is known about the expression of histo‐blood group (ABH) antigens and ABO gene in ovarian tumor tissues. Methods To assess th...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.5476 |
| _version_ | 1797854184899346432 |
|---|---|
| author | Chao Wang Jingjing Zhou Lili Wang Tongyu Xing Hongji Dai Yao Zhou Lisha Qi Yanrui Zhao Caiyun Huang Ding Li Haixin Li Mulin Jun Li Ben Liu Hong Zheng Kexin Chen Lian Li |
| author_facet | Chao Wang Jingjing Zhou Lili Wang Tongyu Xing Hongji Dai Yao Zhou Lisha Qi Yanrui Zhao Caiyun Huang Ding Li Haixin Li Mulin Jun Li Ben Liu Hong Zheng Kexin Chen Lian Li |
| author_sort | Chao Wang |
| collection | DOAJ |
| description | Abstract Background ABO blood groups has been associated with risk of several cancers; however, the results for an association with ovarian cancer are inconsistent and little is known about the expression of histo‐blood group (ABH) antigens and ABO gene in ovarian tumor tissues. Methods To assess the impact of genotype‐derived ABO blood types on the risk of EOC, we conducted a case–control study in 1,870 EOC and 4,829 controls. Expression of A and B antigen in 70 pairs of ovarian tumor tissues and adjacent normal tissues were detected by immunohistochemistry. Gene expression and DNA methylation profiling was conducted in ovarian tumor tissues. Results We identified that blood group A was associated with increased risk for EOC compared to blood group O (OR = 1.18, 95% CI = 1.03–1.36, p = 0.019). Increased frequency of aberrant expression of histo‐blood group antigens was observed in patients with blood group A (76.5%) compared to patients with blood group O (21.1%) and B (5.0%) by immunohistochemistry (p < 0.001). ABO gene expression was down‐regulated in ovarian tumor tissues compared with paired adjacent normal tissues (p = 0.027). In addition, ABO gene expression was positively correlated with NFYB (r = 0.38, p < 0.001) and inversely correlated with DNA methylation level of four CpG sites on ABO gene (cg11879188, r = − 0.3, p = 0.002; cg22535403, r = − 0.30, p = 0.002; cg13506600, r = − 0.22, p = 0.025; cg07241568, r = − 0.21, p = 0.049) in ovarian tumor tissues. Conclusion We identified blood group A was associated with increased EOC risk in Chinese women and provided the clues of the possible molecular mechanisms of blood group A related to ovarian cancer risk. |
| first_indexed | 2024-04-09T20:02:45Z |
| format | Article |
| id | doaj.art-251ee45bcf61477981e92457ad5178bb |
| institution | Directory Open Access Journal |
| issn | 2045-7634 |
| language | English |
| last_indexed | 2024-04-09T20:02:45Z |
| publishDate | 2023-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj.art-251ee45bcf61477981e92457ad5178bb2023-04-02T20:55:01ZengWileyCancer Medicine2045-76342023-03-011267498750710.1002/cam4.5476ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese womenChao Wang0Jingjing Zhou1Lili Wang2Tongyu Xing3Hongji Dai4Yao Zhou5Lisha Qi6Yanrui Zhao7Caiyun Huang8Ding Li9Haixin Li10Mulin Jun Li11Ben Liu12Hong Zheng13Kexin Chen14Lian Li15Department of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Pharmacology, the Province and Ministry Co‐sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences Tianjin Medical University Tianjin ChinaDepartment of Pathology Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Clinical Laboratory Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer Tianjin P. R. ChinaCancer Biobank Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer Tianjin ChinaDepartment of Pharmacology, the Province and Ministry Co‐sponsored Collaborative Innovation Center for Medical Epigenetics, School of Basic Medical Sciences Tianjin Medical University Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaDepartment of Epidemiology and Biostatistics Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Molecular Cancer Epidemiology of Tianjin Tianjin ChinaAbstract Background ABO blood groups has been associated with risk of several cancers; however, the results for an association with ovarian cancer are inconsistent and little is known about the expression of histo‐blood group (ABH) antigens and ABO gene in ovarian tumor tissues. Methods To assess the impact of genotype‐derived ABO blood types on the risk of EOC, we conducted a case–control study in 1,870 EOC and 4,829 controls. Expression of A and B antigen in 70 pairs of ovarian tumor tissues and adjacent normal tissues were detected by immunohistochemistry. Gene expression and DNA methylation profiling was conducted in ovarian tumor tissues. Results We identified that blood group A was associated with increased risk for EOC compared to blood group O (OR = 1.18, 95% CI = 1.03–1.36, p = 0.019). Increased frequency of aberrant expression of histo‐blood group antigens was observed in patients with blood group A (76.5%) compared to patients with blood group O (21.1%) and B (5.0%) by immunohistochemistry (p < 0.001). ABO gene expression was down‐regulated in ovarian tumor tissues compared with paired adjacent normal tissues (p = 0.027). In addition, ABO gene expression was positively correlated with NFYB (r = 0.38, p < 0.001) and inversely correlated with DNA methylation level of four CpG sites on ABO gene (cg11879188, r = − 0.3, p = 0.002; cg22535403, r = − 0.30, p = 0.002; cg13506600, r = − 0.22, p = 0.025; cg07241568, r = − 0.21, p = 0.049) in ovarian tumor tissues. Conclusion We identified blood group A was associated with increased EOC risk in Chinese women and provided the clues of the possible molecular mechanisms of blood group A related to ovarian cancer risk.https://doi.org/10.1002/cam4.5476ABH antigensABO blood groupepithelial ovarian cancerrisk |
| spellingShingle | Chao Wang Jingjing Zhou Lili Wang Tongyu Xing Hongji Dai Yao Zhou Lisha Qi Yanrui Zhao Caiyun Huang Ding Li Haixin Li Mulin Jun Li Ben Liu Hong Zheng Kexin Chen Lian Li ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women Cancer Medicine ABH antigens ABO blood group epithelial ovarian cancer risk |
| title | ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women |
| title_full | ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women |
| title_fullStr | ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women |
| title_full_unstemmed | ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women |
| title_short | ABO blood groups and expression of blood group antigens of epithelial ovarian cancer in Chinese women |
| title_sort | abo blood groups and expression of blood group antigens of epithelial ovarian cancer in chinese women |
| topic | ABH antigens ABO blood group epithelial ovarian cancer risk |
| url | https://doi.org/10.1002/cam4.5476 |
| work_keys_str_mv | AT chaowang abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT jingjingzhou abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT liliwang abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT tongyuxing abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT hongjidai abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT yaozhou abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT lishaqi abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT yanruizhao abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT caiyunhuang abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT dingli abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT haixinli abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT mulinjunli abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT benliu abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT hongzheng abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT kexinchen abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen AT lianli abobloodgroupsandexpressionofbloodgroupantigensofepithelialovariancancerinchinesewomen |